A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the observed adverse events, including potential dose-limiting toxicities (DLT). Subjects will be recruited for this study from the practices of Penn Medicine.
- Study Identifier: 843128
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com